وضعیت فعلی و چشم اندازهای آینده بیماری کروناویروس ۲۰۱۹
ABSTRACT
۱٫ Introduction
۲٫ Structure of SARS-CoV-2
۳٫ Etiology and pathogenesis of COVID-19
۴٫ Epidemiological characteristics of SARS-CoV-2
۵٫ Treatments
۶٫ Conclusion and future directions
References
ABSTRACT
Coronavirus disease 2019 (COVID-19) originated in the city of Wuhan, Hubei Province, Central China, and has spread quickly to 72 countries to date. COVID-19 is caused by a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [previously provisionally known as 2019 novel coronavirus (2019-nCoV)]. At present, the newly identified SARS-CoV-2 has caused a large number of deaths with tens of thousands of confirmed cases worldwide, posing a serious threat to public health. However, there are no clinically approved vaccines or specific therapeutic drugs available for COVID-19. Intensive research on the newly emerged SARS-CoV-2 is urgently needed to elucidate the pathogenic mechanisms and epidemiological characteristics and to identify potential drug targets, which will contribute to the development of effective prevention and treatment strategies. Hence, this review will focus on recent progress regarding the structure of SARS-CoV-2 and the characteristics of COVID-19, such as the aetiology, pathogenesis and epidemiological characteristics.
Introduction
Coronaviruses (CoVs) belong to the subfamily Orthocoronavirinae in the family Coronaviridae, Order Nidovirales. There are four genera within the subfamily Orthocoronavirinae, namely Alphacoronavirus (α-CoV), Betacoronavirus (β-CoV), Gammacoronavirus (γ -CoV) and Deltacoronavirus (δ-CoV) [1,2]. The CoV genome is an enveloped, positive-sense, single-stranded RNA with a size varying between 26 kb and 32 kb, the largest genome of known RNA viruses. Both α- and β-CoV genera are known to infect mammals, whilst δ- and γ -CoVs infect birds. Two recent outbreaks of viral pneumonia caused by β-CoVs are severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). In 2002, an outbreak of SARS was first reported in China and then spread quickly worldwide, resulting in hundreds of deaths with an 11% mortality rate [3,4]. In 2012, MERS first emerged in Saudi Arabia and subsequently spread to other countries, with a fatality rate of 37% [5–۷]. In both of these epidemics, the viruses likely originated from bats and then infected humans through other intermediate animal hosts, e.g. the civet (Paguma larvata) for SARS-CoV and the camel for MERS-CoV [8–۱۰]. Beginning in December 2019, a number of patients with pneumonia of unknown aetiology emerged in Wuhan City, Hubei Province, Central China. Genome sequencing has demonstrated that this pneumonia, named coronavirus disease 2019 (COVID19), is caused by a novel CoV, namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019 novel coronavirus (2019-nCoV) [11–۱۳]. Like SARS-CoV and MERSCoV, this newly emerged SARS-CoV-2 virus belongs to the B lineage of the β-CoVs.